Perioperative anticoagulation management during thoracoscopic ablation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43912502" target="_blank" >RIV/00216208:11120/17:43912502 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/17:N0000005

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.hrthm.2016.11.028" target="_blank" >http://dx.doi.org/10.1016/j.hrthm.2016.11.028</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.hrthm.2016.11.028" target="_blank" >10.1016/j.hrthm.2016.11.028</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Perioperative anticoagulation management during thoracoscopic ablation

Popis výsledku v původním jazyce

With interest we read the article by Romanov et al in the September issue of HeartRhythm.1 They reported that 6 strokes/ transient ischemic attacks (TIAs) occurred perioperatively: 4 (4.5%) in patients undergoing thoracoscopic pulmonary vein isolation þ box lesion only and 2 (2.2%) in patients who underwent an additional occlusion of the left atrial appendage (LAA).1 The exact peri- and postoperative anticoagulation protocol was not reported. Compared with other articles on thoracoscopic ablation (TA) or hybrid ablation, the absence of a description of the peri- and postoperative anticoagulation stands out in this article. In our recent report, 1 stroke and 5 asymptomatic thrombi occurred in 17 patients who underwent TA without heparin and without LAA occlusion, but no strokes or asymptomatic thrombi occurred while on heparin and if the LAA was occluded.2 Compared with endocardial catheter ablation, the risk of stroke/TIA seems to be higher during TA; for example, Probst et al 3 reported 5.1%strokes/TIAs. Therefore, one would expect precise reporting of anticoagulation used perioperatively to address this issue. Unfortunately, the opposite seems to be true; clear description of peri- and postoperative anticoagulation management is obviously lacking.1,3 This is in stark contrast to articles on catheter ablation, in which the anticoagulation protocol is described in detail. In articles on TA, typically the only anticoagulation information given is with regard to withdrawal of warfarin or novel oral anticoagulants before ablation.

Název v anglickém jazyce

Perioperative anticoagulation management during thoracoscopic ablation

Popis výsledku anglicky

With interest we read the article by Romanov et al in the September issue of HeartRhythm.1 They reported that 6 strokes/ transient ischemic attacks (TIAs) occurred perioperatively: 4 (4.5%) in patients undergoing thoracoscopic pulmonary vein isolation þ box lesion only and 2 (2.2%) in patients who underwent an additional occlusion of the left atrial appendage (LAA).1 The exact peri- and postoperative anticoagulation protocol was not reported. Compared with other articles on thoracoscopic ablation (TA) or hybrid ablation, the absence of a description of the peri- and postoperative anticoagulation stands out in this article. In our recent report, 1 stroke and 5 asymptomatic thrombi occurred in 17 patients who underwent TA without heparin and without LAA occlusion, but no strokes or asymptomatic thrombi occurred while on heparin and if the LAA was occluded.2 Compared with endocardial catheter ablation, the risk of stroke/TIA seems to be higher during TA; for example, Probst et al 3 reported 5.1%strokes/TIAs. Therefore, one would expect precise reporting of anticoagulation used perioperatively to address this issue. Unfortunately, the opposite seems to be true; clear description of peri- and postoperative anticoagulation management is obviously lacking.1,3 This is in stark contrast to articles on catheter ablation, in which the anticoagulation protocol is described in detail. In articles on TA, typically the only anticoagulation information given is with regard to withdrawal of warfarin or novel oral anticoagulants before ablation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Heart Rhythm

ISSN

1547-5271

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

1

Strana od-do

"e47"

Kód UT WoS článku

000397243700001

EID výsledku v databázi Scopus

2-s2.0-85007564336